I05 Sustained mutant huntingtin lowering in the brain and cerebrospinal fluid of huntington disease minipigs mediated by AAV5-MIHTT gene therapy
Astrid Valls(UniQure (Netherlands)), Pavlina Konstantinova(Io Therapeutics (United States)), Božena Bohuslavová(Czech Academy of Sciences, Institute of Animal Physiology and Genetics), Cynthia Brouwers(UniQure (Netherlands)), Zdeňka Ellederová(Czech Academy of Sciences, Institute of Animal Physiology and Genetics), Bas Blits(Tilburg University), Melvin M. Evers(UniQure (Netherlands)), Alberto Bresciani(University of Bergamo), Valentina Fodale(IRBM Science Park), Marina Sogorb-González(Io Therapeutics (United States)), Sander van Deventer(UniQure (Netherlands)), Roberta Pintauro(IRBM Science Park), Jan Motlík(Czech Academy of Sciences, Institute of Animal Physiology and Genetics), Jolanda Snapper(UniQure (Netherlands))
Cited by 3
Related Papers
Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair
|Nature Genetics|2009|417
Adipogenesis of skeletal muscle fibro/adipogenic progenitors is affected by the WNT5a/GSK3/β-catenin axis
|Cell Death and Differentiation|2020|149
AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease
|Gene Therapy|2017|104
Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington’s disease
|Journal of Clinical Investigation|2019|101
Proteolytic Activation Cascade of the Netherton Syndrome–Defective Protein, LEKTI, in the Epidermis: Implications for Skin Homeostasis
|Journal of Investigative Dermatology|2011|75